Welnx Therapeutics founded

Welnx Therapeutics was founded on 20 March 2025 with a single conviction: that chronic inflammatory disease is a failure of resolution, and that restoring resolution is a more durable therapeutic strategy than blocking individual cytokines.

The company's approach is to develop small molecules formulated for direct delivery to inflamed tissue, achieving high local concentration while keeping systemic exposure low.